PF614 PATIENT-REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB-RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)

Autor:	Veronique Leblond, Judith Trotman, B. Hauns, Ramón García-Sanz, Christian Buske, E Kastritis, Meletios-Athanassios Dimopoulos, Leonard T. Heffner, Marzia Varettoni, E.G. Poulsen, Constantine S. Tam, Alessandra Tedeschi, Maria Lia Palomba, Jeffrey Matous, Chaim Shustik, Beatrice Mahe, David MacDonald, Charles Herbaux, Steven P. Treon, Jianling Li
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty business.industry Waldenstrom macroglobulinemia Hematology medicine.disease chemistry.chemical_compound chemistry Internal medicine Ibrutinib Medicine Rituximab business medicine.drug
Zdroj:	HemaSphere. 3:260-261
ISSN:	2572-9241
DOI:	10.1097/01.hs9.0000560744.31107.fc
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5c1028d454f9ce0271553159d587e206 https://doi.org/10.1097/01.hs9.0000560744.31107.fc Zobrazit plný text záznamu Plný text